Advaxis, Inc. (ADXS) Exhibits Unusually Rich Pipeline of Clinical Trials
The advance of immunotherapy as a foundational tool in the ongoing fight against cancer and infectious diseases represents one of the biggest developments in modern medicine, alongside stem cell technology, non-invasive diagnostics, and transplant technology. Modern immunotherapy is just now emerging as a viable treatment option, and so its range of possible application is seen as being potentially immense.
Advaxis, a New Jersey based biotech company, is developing the next generation of immunotherapies for cancer and infectious diseases, using a novel approach. The company is bio-engineering a bacteria to secrete antigen/adjuvant fusion protein(s) designed to redirect the human immune response to the bacterium to go after cancer cells. It’s a unique Listeria platform technology that offers advantages, and is the basis for the company’s drug candidates. The company currently has over 15 distinct constructs in various stages of development. ADXS-HPV, their lead candidate, is being evaluated in a number of clinical trials for HPV (Human Papilloma Virus) associated diseases, such as cervical cancer, head and neck cancer, and anal cancer.
In February, 2013, Advaxis announced that the Brown University Oncology Research Group (BrUOG) will
be coordinating a Phase I/II study of ADXS-HPV in 25 patients with HPV-associated anal cancer. Multiple institutions will be involved in the study, which will evaluate both the safety and effectiveness of ADXS-HPV in combination with chemotherapy and radiation treatment. Cancer cells infected with HPV have the tumor associated antigen HPV E7, and the Advaxis drug causes antigen presenting cells to stimulate other immune cells to attack cancer expressing HPV E7. The company now has a series of clinical trials under study, including three Phase II trials, two Phase I/II trials, and three Phase I trials, significant for a small-cap biotech company.
For additional information, visit www.Advaxis.com
Please see disclaimer on our profile |
